文献速递腹部CT

高分辨率胰腺CT评估胰腺导管腺癌可切除性的多中心前瞻性研究

High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
PubMed 文献 · Eur Radiol · 2023-03-29

该多中心前瞻性研究纳入138例PDAC手术候选者,采用80 kVp薄层胰腺CT按NCCN指南评估可切除性。在高分辨率CT上判定为可切除者,直接手术和新辅助治疗后R0切除率分别为88.7%和90.9%;预测R0切除的AUC为0.784,敏感度87.4%、特异度48.6%、准确率77.5%。

要点

  • 80 kVp薄层胰腺CT按NCCN指南评估PDAC可切除性,可切除者R0切除率高。
  • 高分辨率CT预测R0切除的敏感度87.4%、特异度48.6%、AUC 0.784。
  • 新辅助治疗后肿瘤反应与R0切除显著相关(OR=38.99,p=0.016)。

核心结论

  • 80 kVp薄层胰腺CT在评估PDAC可切除性方面诊断性能优良,可切除患者直接手术和新辅助治疗后R0切除率分别达88.7%和90.9%。

研究设计与样本

  • 多中心前瞻性研究,纳入6家三级转诊医院138例PDAC手术候选者(NCT03895177)。
  • 所有患者行80 kVp管电压、1 mm重建间隔的胰腺CT,各中心按NCCN指南前瞻性评估可切除性。
  • 可切除性分为可切除、交界可切除和不可切除三类,以R0切除为参考标准之一。

诊断标准与关键数值

  • 高分辨率CT预测R0切除的AUC为0.784,敏感度87.4%(90/103)、特异度48.6%(17/35)、准确率77.5%(107/138)。
  • 直接手术患者中,可切除、交界可切除、不可切除的R0切除率分别为88.7%(47/53)、52.4%(11/21)、0.0%(0/4)。
  • 新辅助治疗患者中,可切除、交界可切除、不可切除的R0切除率分别为90.9%(20/22)、76.7%(23/30)、25.0%(2/8)。
  • 新辅助治疗后肿瘤反应与R0切除显著相关(OR=38.99,p=0.016)。

临床应用与阅片要点

  • 采用80 kVp薄层胰腺CT并按NCCN指南评估PDAC可切除性,可帮助筛选适合直接手术的患者。
  • 交界可切除和不可切除患者的R0切除率明显较低,报告时应准确描述肿瘤与血管的关系。
  • 新辅助治疗后应关注肿瘤反应评估,其与R0切除显著相关。

局限性

  • 本研究为前瞻性多中心设计,原文未报告其他明显局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This prospective multicenter study aimed to evaluate the diagnostic performance of 80-kVp thin-section pancreatic CT in determining pancreatic ductal adenocarcinoma (PDAC) resectability according to the recent National Comprehensive Cancer Network (NCCN) guidelines.

METHODS: We prospectively enrolled surgical resection candidates for PDAC from six tertiary referral hospitals (study identifier: NCT03895177). All participants underwent pancreatic CT using 80 kVp tube voltage with 1-mm reconstruction interval. The local resectability was prospectively evaluated using NCCN guidelines at each center and classified into three categories: resectable, borderline resectable, and unresectable.

RESULTS: A total of 138 patients were enrolled; among them, 60 patients underwent neoadjuvant therapy. R0 resection was achieved in 103 patients (74.6%). The R0 resection rates were 88.7% (47/53), 52.4% (11/21), and 0.0% (0/4) for resectable, borderline resectable, and unresectable disease, respectively, in 78 patients who underwent upfront surgery. Meanwhile, the rates were 90.9% (20/22), 76.7% (23/30), and 25.0% (2/8) for resectable, borderline resectable, and unresectable PDAC, respectively, in patients who received neoadjuvant therapy. The area under curve of high-resolution CT in predicting R0 resection was 0.784, with sensitivity, specificity, and accuracy of 87.4% (90/103), 48.6% (17/35), and 77.5% (107/138), respectively. Tumor response was significantly associated with the R0 resection after neoadjuvant therapy (odds ratio [OR] = 38.99, p = 0.016).

CONCLUSION: An 80-kVp thin-section pancreatic CT has excellent diagnostic performance in assessing PDAC resectability, enabling R0 resection rates of 88.7% and 90.9% for patients with resectable PDAC who underwent upfront surgery and patients with resectable PDAC after neoadjuvant therapy, respectively.

KEY POINTS: • The margin-negative (R0) resection rates were 88.7% (47/53), 52.4% (11/21), and 0.0% (0/4) for resectable, borderline resectable, and unresectable pancreatic ductal adenocarcinoma (PDAC), respectively, on 80-kVp thin-section pancreatic CT in the 78 patients who underwent upfront surgery. • Among the 60 patients who underwent neoadjuvant therapy, the R0 rates were 90.9% (20/22), 76.7% (23/30), and 25.0% (2/8) for resectable, borderline resectable, and unresectable PDAC, respectively. • Tumor response, along with the resectability status on pancreatic CT, was significantly associated with the R0 resection rate after neoadjuvant therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lee, Ha, Jang, et al. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Eur Radiol. 2023. PMID: 36988715. doi:10.1007/s00330-023-09584-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。